Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

NCT ID: NCT04730635

Last Updated: 2024-10-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-23
• Study Completion Date: 2023-02-06

Brief Summary

The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo among participants with mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD). The primary study hypothesis is that the average percentage of correct responses on one card learning (OCL) task will be ≥2 percentage points in participants receiving donepezil compared with participants receiving placebo.

Conditions

Alzheimer's Disease; Mild Cognitive Impairment

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Donepezil

Participants receive donepezil in doses up to 10 mg once daily (QD), orally in a scheduled titration for Days 1-56. The total treatment duration is 56 days.

Group Type: EXPERIMENTAL

Donepezil

Intervention Type: DRUG

Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.

Placebo

Participants receive placebo QD, orally for Days 1-56. The total treatment duration is 56 Days.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Dose matched placebo capsule QD, orally for Days 1-56.

Interventions

Donepezil

Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.

Intervention Type: DRUG

Placebo

Dose matched placebo capsule QD, orally for Days 1-56.

Intervention Type: DRUG

Other Intervention Names

MK-0000; Donepezil hydrochloride; Aricept

Eligibility Criteria

Inclusion Criteria

• Has an Mini Mental State Examination (MMSE) score between 18 and 28 (inclusive) at Screening (Visit 1) and Baseline (Visit 2)
• Has a diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD)
• Has an Modified Hachinski Ischemia Scale (MHIS) score of ≤4
• Must have a reliable and competent study partner/informant who accompanies participant to study visits and participates in assessments
• Be willing to provide a blood sample for Apolipoprotein E (APOE) genotyping
• Does not have intellectual disability
• Be able to speak, read, hear, and understand the language of the study staff and the Informed Consent Form (ICF)
• Be able and willing to adhere to the study visit schedule
• Have visual acuity, visual function, hearing, and gross and fine motor skills adequate to support study participation
• Be capable of performing the Cogstate battery assessments, as demonstrated at the Baseline/Familiarization Visit (Visit 2)
• A female participant is eligible to participate if she is a woman of nonchildbearing potential (WONCBP)

Exclusion Criteria

• Is at imminent risk of self-harm
• Has evidence of a clinically relevant neurological disorder other than AD at screening, including but not limited to: Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive supranuclear palsy, dementia with Lewy bodies, other types of dementia, neurosyphilis or that led to persistent cognitive deficits, or has a history of seizures or epilepsy within the last 5 years before screening
• Has a known history of stroke or has a diagnosis of vascular dementia
• Has history of multiple episodes of head trauma, or head trauma resulting in protracted loss of consciousness, or serious infectious disease affecting the brain, within the prior 3-5 years
• Has evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), including schizophrenia or other psychotic disorder, bipolar disorder, major depression, or delirium
• Has a recent or ongoing, uncontrolled, clinically significant medical condition within 2 months of the Screening visit
• Has a history of cancer
• Has a relative contraindication to donepezil including sick sinus syndrome, first, second, or third-degree heart block, bradycardia, active gastrointestinal (GI) bleeding, Zollinger-Ellison syndrome, uncontrolled peptic ulcer disease, or uncontrolled asthma
• Has a history of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food. Exception: Participants with selected allergies may be enrolled with Sponsor's approval
• Is positive for Hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV) [participants with a history of chronic hepatitis C virus with a documented cure and/or a positive serologic test for HCV with a negative HCV viral load may be included]
• Has clinically significant vitamin B12 or folate deficiency in the 6 months immediately before screening, or vitamin B12 or folate deficiency in addition to increased serum homocysteine and methylmalonic acid levels at screening
• Has prior AD treatment
• Has participated in another investigational study within 4 weeks
• Has a known history of structural changes on screening magnetic resonance imaging (MRI) scan that are clinically important, including signs indicative of vascular dementia, large infarct, lacunes in critical areas, space-occupying lesions, or extensive white matter disease
• Is unwilling to or not eligible to undergo a MRI scan (if a prior MRI scan is not available)
• Is pregnant, is attempting to become pregnant, or is nursing children
• Has a history of alcoholism or drug dependency/abuse within the last 5 years prior to the Screening visit
• Consumes greater than 3 glasses of alcoholic beverages per day
• Consumes excessive amounts, defined as greater than 6 servings of coffee, tea, cola, energy drinks, or other caffeinated beverages per day
• Is a regular user of cannabis, any illicit drugs or has a history of drug abuse within approximately 5 years. A participant who is a recreational user of cannabis or other drugs within the past 2 years can be enrolled as long as recreational use does not meet the definition of drug abuse and participant agrees to refrain from substance use for duration of study participation
• Participants must have a negative urine drug screen (UDS) prior to randomization
• Had major surgery within 3 months prior to the Screening visit that would interfere in the participant's ability to fully participate in the study
• Has undergone neuropsychological testing (including the MMSE) or cognitive remediation in the past 4 weeks
• Is or has an immediate family member who is investigational site or Sponsor staff directly involved with this study

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

Collaborative Neuroscience Network ( Site 0010)

Long Beach, California, United States

Velocity Clinical Research, Hallandale Beach ( Site 0013)

Hallandale, Florida, United States

Charter Research - Lady Lake ( Site 0025)

Lady Lake, Florida, United States

iResearch Atlanta ( Site 0005)

Decatur, Georgia, United States

iResearch Savannah ( Site 0023)

Savannah, Georgia, United States

Pennington Biomedical Research Center ( Site 0006)

Baton Rouge, Louisiana, United States

Insight Clinical Trials ( Site 0020)

Beachwood, Ohio, United States

North Texas Clinical Trials - Fort Worth - West Rosedale ( Site 0022)

Fort Worth, Texas, United States

Royal Adelaide Hospital-CALHN Memory Trials ( Site 0031)

Adelaide, South Australia, Australia

Austin Health ( Site 0030)

Heidelberg, Victoria, Australia

Countries

United States; Australia

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

http://www.merckclinicaltrials.com

Merck Clinical Trials Information

Other Identifiers

MK-0000-413

Identifier Type: OTHER

Identifier Source: secondary_id

0000-413

Identifier Type: -

Identifier Source: org_study_id